{"protocolSection":{"identificationModule":{"nctId":"NCT02810509","orgStudyIdInfo":{"id":"Warfarin TTR-01"},"organization":{"fullName":"Inje University","class":"OTHER"},"briefTitle":"Quality of Anticoagulation With Warfarin in Patient With Atrial Fibrillation for Secondary Stroke Prevention in Korea","officialTitle":"Quality of Anticoagulation With Warfarin in Patient With Atrial Fibrillation for Secondary Stroke Prevention in Korea"},"statusModule":{"statusVerifiedDate":"2018-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-06"},"primaryCompletionDateStruct":{"date":"2016-10","type":"ACTUAL"},"completionDateStruct":{"date":"2016-10","type":"ACTUAL"},"studyFirstSubmitDate":"2015-12-23","studyFirstSubmitQcDate":"2016-06-20","studyFirstPostDateStruct":{"date":"2016-06-23","type":"ESTIMATED"},"resultsFirstSubmitDate":"2017-01-25","resultsFirstSubmitQcDate":"2019-08-08","resultsFirstPostDateStruct":{"date":"2019-09-13","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-08-08","lastUpdatePostDateStruct":{"date":"2019-09-13","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Keun-Sik Hong","investigatorTitle":"Professor","investigatorAffiliation":"Inje University"},"leadSponsor":{"name":"Inje University","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The current study aims to assess the quality of anticoagulation with warfarin in real world practice of secondary stroke prevention in Korean patients with Atrial fibrillation (AF) and to explore predictors for poor International Normalized Range (INR) control.","detailedDescription":"* To assess the quality of anticoagulation with warfarin in real world practice of Korea for secondary stroke prevention in patients with AF-related Cardioembolic (CE) stroke 1) who initiated warfarin therapy and treatment at least for more than 7 days of warfarin adjustment period (warfarin-initiated cohort), and 2) who initiated and maintained warfarin therapy at least for more than 90 days after the 7 days of warfarin adjustment period (long-term warfarin-treated cohort).\n* To explore predictors for poor INR control."},"conditionsModule":{"conditions":["Atrial Fibrillation","Stroke"],"keywords":["Wafarin","Cardioembolic (CE) stroke","ischemic stroke"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"RETROSPECTIVE"},"enrollmentInfo":{"count":1814,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Short-term Warfarin-treated cohort","description":"1. admission due to AF-related ischemic stroke (known AF or newly detected AF)\n2. for TTR calculation, the number of consecutive INR measurements ≥3 after the 7 days of warfarin adjustment\n3. TTR evaluable days \\< 90 days"},{"label":"Long-term Warfarin-treated cohort","description":"1. admission due to AF-related ischemic stroke (known AF or newly detected AF)\n2. long-term warfarin therapy at least for more than 90 days after the 7 days of warfarin adjustment period\n3. for TTR calculation, the number of consecutive INR measurements ≥3 after the 7 days of warfarin adjustment\n4. TTR evaluable days ≥ 90 days"}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Time in TTR, the Percentage of Time in the Therapeutic Range of INR Between 2.0-3.0.","description":"The primary outcome is TTR as measured by the percentage of time in the therapeutic range of INR between 2.0-3.0, using the Rosendaal linear interpolation method.","timeFrame":"We will analyze INR data of patients who had AF-related ischemic stroke and were treated with warfarin therapy at least for more than 7 days of warfarin adjustment period. (The INR follow up duration: 1 ~ maximum 3 years)"}],"secondaryOutcomes":[{"measure":"Percentage of INR Values in the Therapeutic Range of 2.0-3.0: Numbers of INR Values Within the Therapeutic Range by the Total Numbers of INR Measured.","description":"The secondary outcome is the percentage of INR values in the therapeutic range of 2.0-3.0: numbers of INR values within the therapeutic range divided by the total numbers of INR measured.","timeFrame":"We will analyze INR data of patients who had AF-related ischemic stroke and were treated with warfarin therapy at least for more than 7 days of warfarin adjustment period. (The INR follow up duration: 1 ~ maximum 3 years)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nInclusion criteria for the warfarin-initiated cohort\n\n1. Admission due to AF-related ischemic stroke\n2. Initiation of warfarin therapy and treatment at least for more than 7 days of warfarin adjustment period\n3. For TTR calculation, available consecutive INR values ≥3 after the 7 days of warfarin adjustment\n\nInclusion criteria for the long-term warfarin-treated cohort\n\n1. Admission due to AF-related ischemic stroke\n2. Long-term warfarin therapy at least for more than 90 days after the 7 days of warfarin adjustment period\n3. For TTR calculation, available consecutive INR values ≥3 after the 7 days of warfarin adjustment\n4. TTR evaluable days ≥ 90 days\n\nExclusion Criteria:\n\n1. AF with mechanical valve\n2. Enrollment in anticoagulation randomized clinical trial\n3. Enrollment in studies affecting the target INR range.","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"],"studyPopulation":"Consecutive patients who admitted to 16 participating centers due to AF-related ischemic stroke between Jan 1, 2011 and Dec 31, 2012 and started warfarin therapy for secondary stroke prevention will be enrolled in this study. The number of patients is expected to be 2,217 for the warfarin-initiated cohort and 1,057 for the long-term warfarin-treated cohort.","samplingMethod":"PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Keun-Sik Hong, MD, Phd","affiliation":"Department of Neurology, Ilsan Paik Hospital Inje University","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Hallym University College of Medicine","city":"Anyang","country":"Korea, Republic of","geoPoint":{"lat":37.3925,"lon":126.92694}},{"facility":"Dong-A University College of Medicine","city":"Busan","country":"Korea, Republic of","geoPoint":{"lat":35.10278,"lon":129.04028}},{"facility":"Yeungnam University School of Medicine","city":"Daegu","country":"Korea, Republic of","geoPoint":{"lat":35.87028,"lon":128.59111}},{"facility":"Dongguk University Ilsan Hospital","city":"Goyang","country":"Korea, Republic of","geoPoint":{"lat":37.65639,"lon":126.835}},{"facility":"Chonnam National University Medical School","city":"Gwangju","country":"Korea, Republic of","geoPoint":{"lat":35.15472,"lon":126.91556}},{"facility":"Ilsan Paik Hospital Inje University","city":"Ilsan","country":"Korea, Republic of","geoPoint":{"lat":35.5,"lon":129.43333}},{"facility":"Inha University Hospital","city":"Incheon","country":"Korea, Republic of","geoPoint":{"lat":37.45646,"lon":126.70515}},{"facility":"Jeju National University Hospital, Jeju National University College of Medicine","city":"Jeju","country":"Korea, Republic of","geoPoint":{"lat":33.50972,"lon":126.52194}},{"facility":"Seoul National University Bundang Hospital","city":"Seongnam","country":"Korea, Republic of","geoPoint":{"lat":37.43861,"lon":127.13778}},{"facility":"Eulji General Hospital, Eulji University School of Medicine","city":"Seoul","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Korea University College of Medicine","city":"Seoul","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Samsung Medical Center, Sungkyunkwan University School of Medicine","city":"Seoul","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Seoul Medical Center","city":"Seoul","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Seoul National University College of Medicine","city":"Seoul","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Soonchunhyang University College of Medicine","city":"Seoul","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Soonchunhyang University","city":"Seoul","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"University of Ulsan College of Medicine","city":"Seoul","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Yonsei University College of Medicine","city":"Seoul","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Short Term Wafarin-treated Cohort","description":"1. admission due to AF-related ischemic stroke (known AF or newly detected AF)\n2. for TTR calculation, the number of consecutive INR measurements ≥3 after the 7 days of warfarin adjustment\n3. TTR evaluable days \\< 90 days"},{"id":"FG001","title":"Long Term Warfarin-treated Cohort","description":"1. admission due to AF-related ischemic stroke (known AF or newly detected AF)\n2. long-term warfarin therapy at least for more than 90 days after the 7 days of warfarin adjustment period\n3. for TTR calculation, the number of consecutive INR measurements ≥3 after the 7 days of warfarin adjustment\n4. TTR evaluable days ≥ 90 days"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"584"},{"groupId":"FG001","numSubjects":"1230"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"584"},{"groupId":"FG001","numSubjects":"1230"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Overall number of Baseline participants are divided by short term and Long term Warfarin-treated cohort.","groups":[{"id":"BG000","title":"Short Term Wafarin-treated Cohort","description":"1. Admission due to AF-related ischemic stroke (known AF or newly detected AF)\n2. for TTR calculation, the number of consecutive INR measurements ≥3 after the 7 days of warfarin adjustment\n3. TTR evaluable days \\< 90 days"},{"id":"BG001","title":"Long Term Warfarin-treated Cohort","description":"1. Admission due to AF-related ischemic stroke\n2. Long-term warfarin therapy at least for more than 90 days after the 7 days of warfarin adjustment period\n3. For Time in TTR calculation, available consecutive INR values ≥3 after the 7 days of warfarin adjustment\n4. TTR evaluable days ≥ 90 days"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"584"},{"groupId":"BG001","value":"1230"},{"groupId":"BG002","value":"1814"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"73.71","spread":"9.60"},{"groupId":"BG001","value":"70.08","spread":"9.73"},{"groupId":"BG002","value":"71.25","spread":"9.83"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"298"},{"groupId":"BG001","value":"523"},{"groupId":"BG002","value":"821"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"286"},{"groupId":"BG001","value":"707"},{"groupId":"BG002","value":"993"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Time in TTR, the Percentage of Time in the Therapeutic Range of INR Between 2.0-3.0.","description":"The primary outcome is TTR as measured by the percentage of time in the therapeutic range of INR between 2.0-3.0, using the Rosendaal linear interpolation method.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage of time in therapeutic range","timeFrame":"We will analyze INR data of patients who had AF-related ischemic stroke and were treated with warfarin therapy at least for more than 7 days of warfarin adjustment period. (The INR follow up duration: 1 ~ maximum 3 years)","groups":[{"id":"OG000","title":"Short-term Cohort","description":"1. admission due to AF-related ischemic stroke (known AF or newly detected AF)\n2. for TTR calculation, the number of consecutive INR measurements ≥3 after the 7 days of warfarin adjustment\n3. TTR evaluable days \\< 90 days"},{"id":"OG001","title":"Long-term Cohort","description":"1. admission due to AF-related ischemic stroke (known AF or newly detected AF)\n2. long-term warfarin therapy at least for more than 90 days after the 7 days of warfarin adjustment period\n3. for TTR calculation, the number of consecutive INR measurements ≥3 after the 7 days of warfarin adjustment\n4. TTR evaluable days ≥ 90 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"584"},{"groupId":"OG001","value":"1230"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.4","spread":"26.3"},{"groupId":"OG001","value":"49.1","spread":"20.8"}]}]}]},{"type":"SECONDARY","title":"Percentage of INR Values in the Therapeutic Range of 2.0-3.0: Numbers of INR Values Within the Therapeutic Range by the Total Numbers of INR Measured.","description":"The secondary outcome is the percentage of INR values in the therapeutic range of 2.0-3.0: numbers of INR values within the therapeutic range divided by the total numbers of INR measured.","reportingStatus":"POSTED","paramType":"COUNT_OF_UNITS","unitOfMeasure":"Number of INR measured","timeFrame":"We will analyze INR data of patients who had AF-related ischemic stroke and were treated with warfarin therapy at least for more than 7 days of warfarin adjustment period. (The INR follow up duration: 1 ~ maximum 3 years)","typeUnitsAnalyzed":"Number of INR measured","denomUnitsSelected":"Number of INR measured","groups":[{"id":"OG000","title":"Short-term Cohort","description":"1. Admission due to AF-related ischemic stroke (known AF or newly detected AF)\n2. for TTR calculation, the number of consecutive INR measurements ≥3 after the 7 days of warfarin adjustment\n3. TTR evaluable days \\< 90 days"},{"id":"OG001","title":"Long-term Cohort","description":"1. Admission due to AF-related ischemic stroke\n2. Long-term warfarin therapy at least for more than 90 days after the 7 days of warfarin adjustment period\n3. For Time in TTR calculation, available consecutive INR values ≥3 after the 7 days of warfarin adjustment\n4. TTR evaluable days ≥ 90 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"584"},{"groupId":"OG001","value":"1230"}]},{"units":"Number of INR measured","counts":[{"groupId":"OG000","value":"8693"},{"groupId":"OG001","value":"33941"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3900"},{"groupId":"OG001","value":"15120"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"This is an investigator-initiated study of a retrospective observation study therefore, adverse events and serious adverse events are not collected through this study.","description":"This is an investigator-initiated study of a retrospective observation study therefore, adverse events and serious adverse events are not collected through this study.","eventGroups":[{"id":"EG000","title":"Warfarin-initiated Cohort","description":"1. Admission due to AF-related ischemic stroke\n2. Initiation of warfarin therapy and treatment at least for more than 7 days of warfarin adjustment period\n3. For Time in therapeutic range (TTR) calculation, available consecutive INR values ≥3 after the 7 days of warfarin adjustment","seriousNumAffected":0,"seriousNumAtRisk":0,"otherNumAffected":0,"otherNumAtRisk":0},{"id":"EG001","title":"Long Term Warfarin-treated Cohort","description":"1. Admission due to AF-related ischemic stroke\n2. Long-term warfarin therapy at least for more than 90 days after the 7 days of warfarin adjustment period\n3. For Time in TTR calculation, available consecutive INR values ≥3 after the 7 days of warfarin adjustment\n4. TTR evaluable days ≥ 90 days","seriousNumAffected":0,"seriousNumAtRisk":0,"otherNumAffected":0,"otherNumAtRisk":0}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Keun-Sik Hong, MD, PhD, Prof","organization":"Ilsan Paik Hospital Inje University","email":"nrhks@paik.ac.kr","phone":"82-31-910-7680"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M11997","name":"Neoplasm Metastasis","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M17292","name":"Warfarin","relevance":"LOW"}],"browseBranches":[{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":true}